Analysis of the latest stocks of Bestech’s innovation board: Servo equipment leading products lead to long-term competition

Analysis of the latest stocks of Bestech’s innovation board: Servo equipment leading products lead to long-term competition
A leading domestic magnetic resonance equipment company with a rich product line.The company was founded in 2000 and has long been focusing on the manufacture of large-scale medical imaging equipment.The company’s products are assembled in nearly 2,000 domestic medical institutions and exported to more than 20 countries around the world.At present, the company’s products are based on magnetic resonance, covering five series of medical X-ray equipment, nuclear medicine equipment, color ultrasound diagnostic system, and medical information software.The company’s plasma product line is complete and its categories are abundant. In 2017, domestic sales and holdings replaced the domestic brands.The company’s chairman and general manager Peng Jianzhong directly holds the company44.The 26% equity is the actual controller of the company, and the remaining shareholders hold 5% of the shares. Revenue and profits have grown steadily, and costs and debt ratios have been properly controlled.The company’s revenue for 2016-2018 was 3.56,4.15, 4.710,000 yuan; net profit to mother is 0.93, 1.03, 1.The net cash flow from operating activities was RMB 408.8, 4751, 39.49 杭州夜网论坛 million, and gross profit margins were 46.28%, 47.11%, 46.88%; R & D expenses are 2090, 2558, and 44.77 million yuan, and the proportion of R & D expenses to revenue is 5.87%, 6.16%, 9.50%; selling expenses were 4,474, 4720, and 52.47 million yuan, respectively, and selling expenses as a percentage of revenue were 12.56%, 11.37%, 11.14%; asset-liability ratios are 37.89%, 29.34%, 25.91%.The company’s performance has grown steadily, expenses have been properly controlled, and its overall financial position is good. Adhere to the R & D-driven high-end product strategy, and benefit from long-term policy dividends.The company is one of the first batch of “National Emerging Enterprises”. It has long adhered to the path of independent innovation development, continued to promote research and development, and promoted high-end product transformation.A number of products were selected into the “Outstanding Domestic Medical Equipment Product Catalog” and the national “First (set) Major Technical Equipment Plan”.The company continues to upgrade its products and continuously improve its performance.Company 3.The 0T superconducting magnetic resonance imaging system has obtained the CFDA registration certificate in January 2018, and the company has become the second domestic company capable of producing this high-end magnetic resonance equipment.The company has decided that the research and development costs increase year by year. The products under development also include 64-row spiral CT, medical linear accelerators, and 7.0T superconducting magnetic resonance imaging system and other cutting-edge medical imaging equipment. The company complies with the “Listing Rules for Science and Technology Innovation Board” 2.1.2 The first condition.The company’s net profit in 2017 and 2018 were 1.03, 1.08 ‰, the expected market value is not less than 10 ‰, in line with the “Listing Rules for Science and Technology Innovation Board”1.2 The first item: The estimated market value is not less than RMB 10 million. The net profit of the last two years has replaced the positive and gradually the net profit does not exceed RMB 50 million. risk warning.Competition of similar products intensifies risks, R & D risks, and changes in industry policies.